Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2017

20.04.2017 | Original Article

68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging

verfasst von: Lilian Yuri Itaya Yamaga, Marcelo L. Cunha, Guilherme C. Campos Neto, Marcio R. T. Garcia, Ji H. Yang, Cleber P. Camacho, Jairo Wagner, Marcelo B. G. Funari

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to prospectively compare the detection rate of 68Ga-DOTATATE PET-CT with 111In-octreotide SPECT-CT and conventional imaging (CI) in medullary thyroid carcinoma (MTC) patients with increased calcitonin (Ctn) levels but negative CI after thyroidectomy.

Methods

Fifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent 68Ga-DOTATATE PET-CT, 111In-octreotide SPECT-CT and CI. Histopathology, CI and biochemical/clinical/imaging follow-up were used as the reference standard. PET/CT, SPECT/CT and CI were compared in a lesion-based and organ-based analysis.

Results

PET/CT evidenced recurrence in 14 of 15 patients. There were 13 true positive (TP), 1 true negative (TN), 1 false positive (FP) and no false negative (FN) cases, resulting in a sensitivity and accuracy of 100% and 93%. SPECT/CT was positive in 6 of 15 cases. There were 6 TP, 2 TN, 7 FN and no FP cases, resulting in a sensitivity of 46% and accuracy of 53%. CI procedures detected tumor lesions in 14 of 15 patients. There were 13 TP, 1TN, 1 FP and no FN cases with a sensitivity of 100% and accuracy of 93%.
A significantly higher number of lesions was detected by PET/CT (112 lesions, p = 0.005) and CI (109 lesions, p = 0.005) in comparison to SPECT/CT (16 lesions). There was no significant difference between PET/CT and CI for the total number of detected lesions (p = 0.734). PET/CT detected more lesions than SPECT/CT regardless of the organ. PET/CT detected more bone lesions but missed some neck nodal metastases evidenced by CI. The number of lesions per region demonstrated by PET/CT and CI were similar in the other sites.

Conclusion

68Ga-DOTATATE PET/CT is superior to 111In-octreotide SPECT/CT for the detection of recurrent MTC demonstrating a significantly higher number of lesions. 68Ga-DOTATATE PET/CT showed a superior detection rate compared to CI in demonstrating bone metastases.
Literatur
1.
Zurück zum Zitat Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer. 2000;88:1139–48.CrossRefPubMed Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer. 2000;88:1139–48.CrossRefPubMed
2.
Zurück zum Zitat Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.CrossRefPubMed Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.CrossRefPubMed
3.
Zurück zum Zitat Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med Mol Imaging. 2001;28:64–71.CrossRef Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med Mol Imaging. 2001;28:64–71.CrossRef
4.
Zurück zum Zitat Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32.CrossRefPubMed Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32.CrossRefPubMed
5.
Zurück zum Zitat Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641–9.CrossRef Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641–9.CrossRef
6.
Zurück zum Zitat Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol. 1995;42:31–7.CrossRef Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol. 1995;42:31–7.CrossRef
7.
Zurück zum Zitat Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary carcinoma. J Clin Endocrinol Metab. 1993;76:1413–7.PubMed Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary carcinoma. J Clin Endocrinol Metab. 1993;76:1413–7.PubMed
8.
Zurück zum Zitat Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–6.PubMed Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–6.PubMed
9.
Zurück zum Zitat Bernà L, Chico A, Matías-Guiu X, et al. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 1998;25:1482–8.CrossRef Bernà L, Chico A, Matías-Guiu X, et al. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 1998;25:1482–8.CrossRef
10.
Zurück zum Zitat Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708–16.PubMed Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708–16.PubMed
11.
Zurück zum Zitat Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with Somatostatin receptor Scintigraphy and CT. J Nucl Med. 2007;48:508–18.CrossRefPubMed Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with Somatostatin receptor Scintigraphy and CT. J Nucl Med. 2007;48:508–18.CrossRefPubMed
12.
Zurück zum Zitat Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875–82.CrossRefPubMed Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875–82.CrossRefPubMed
13.
Zurück zum Zitat Conry BG, Papathanasiou ND, Prakash V, et al. Comparison of 68Ga-DOTATATE and 18fluordeoxyglucose PET⁄CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57.CrossRefPubMed Conry BG, Papathanasiou ND, Prakash V, et al. Comparison of 68Ga-DOTATATE and 18fluordeoxyglucose PET⁄CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57.CrossRefPubMed
14.
Zurück zum Zitat Treglia G, Castaldi P, Villani MF, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET⁄CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–80.CrossRefPubMed Treglia G, Castaldi P, Villani MF, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET⁄CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–80.CrossRefPubMed
15.
Zurück zum Zitat Colturato MT, Dias LA, Pujatti PB, et al. Validação da Produção Automatizada do DOTATATO-68Ga no IPEN-CNEN/SP. In: XXVI Congresso Brasileiro de Medicina Nuclear, 2012, Salvador - BA. ALASBIMN Journal, 2012. Colturato MT, Dias LA, Pujatti PB, et al. Validação da Produção Automatizada do DOTATATO-68Ga no IPEN-CNEN/SP. In: XXVI Congresso Brasileiro de Medicina Nuclear, 2012, Salvador - BA. ALASBIMN Journal, 2012.
17.
Zurück zum Zitat Naswa N, Sharma P, Suman Kc S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun. 2012;33(7):766–74.CrossRefPubMed Naswa N, Sharma P, Suman Kc S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun. 2012;33(7):766–74.CrossRefPubMed
18.
Zurück zum Zitat Rufini V, Castaldi P, Treglia G, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother. 2008;62:139–46.CrossRefPubMed Rufini V, Castaldi P, Treglia G, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother. 2008;62:139–46.CrossRefPubMed
19.
Zurück zum Zitat Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphy and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphy and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed
20.
Zurück zum Zitat Reubi JC, Krenning E, Lamberts SWJ, Kvols L. In vitro detection of somatostatin receptors in human tumors. Metabolism. 1992;41:104–10.CrossRefPubMed Reubi JC, Krenning E, Lamberts SWJ, Kvols L. In vitro detection of somatostatin receptors in human tumors. Metabolism. 1992;41:104–10.CrossRefPubMed
21.
Zurück zum Zitat Binnebeek SV, Vanbilloen B, Baete K, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26:900–9.CrossRefPubMed Binnebeek SV, Vanbilloen B, Baete K, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26:900–9.CrossRefPubMed
22.
Zurück zum Zitat Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial staging of lymphoma with octreotide and other receptor imaging agents. Sem Nucl Med. 2005;35:176–85.CrossRef Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial staging of lymphoma with octreotide and other receptor imaging agents. Sem Nucl Med. 2005;35:176–85.CrossRef
23.
Zurück zum Zitat Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of Somatostatin receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704–12.CrossRefPubMed Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of Somatostatin receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704–12.CrossRefPubMed
24.
Zurück zum Zitat Treglia G, Villani MF, Giordano A, Rufini. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.CrossRefPubMed Treglia G, Villani MF, Giordano A, Rufini. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.CrossRefPubMed
25.
Zurück zum Zitat Kauhanen S, Schalin-Jäntti C, Seppänen M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52:1855–63.CrossRefPubMed Kauhanen S, Schalin-Jäntti C, Seppänen M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52:1855–63.CrossRefPubMed
26.
Zurück zum Zitat Froberg AC, de Jong M, Nock BA, et al. Comparison of three radiolabeled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265–72.CrossRefPubMedPubMedCentral Froberg AC, de Jong M, Nock BA, et al. Comparison of three radiolabeled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265–72.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. Am J Roentgenol. 2013;201:W867–76.CrossRef Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. Am J Roentgenol. 2013;201:W867–76.CrossRef
28.
Zurück zum Zitat Wells Jr SA, Asa SL, Dralle H, et al. American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMedPubMedCentral Wells Jr SA, Asa SL, Dralle H, et al. American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMedPubMedCentral
Metadaten
Titel
68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging
verfasst von
Lilian Yuri Itaya Yamaga
Marcelo L. Cunha
Guilherme C. Campos Neto
Marcio R. T. Garcia
Ji H. Yang
Cleber P. Camacho
Jairo Wagner
Marcelo B. G. Funari
Publikationsdatum
20.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3701-9

Weitere Artikel der Ausgabe 10/2017

European Journal of Nuclear Medicine and Molecular Imaging 10/2017 Zur Ausgabe